BURLINGTON, Mass.—A new license agreement has been announced between Dyax Corp. and Eclipse Therapeutics Inc. Dyax has provided Eclipse with an exclusive worldwide license to develop and commercialize preclinical fully human antibodies discovered with Dyax’s phage display technology for oncology indications. In return, Eclipse will pay Dyax an initial license fee, as well as clinical development and sales milestones and royalties on worldwide net sales of any commercialized products. “Our oncology pipeline focuses on identifying functional therapeutics that specifically inhibit CSC targets critical to the maintenance of cancer stem cells at the root of cancer. Dyax’s expertise in antibody therapeutic discovery accelerates these efforts, allowing us to expand our library of product candidates,” Dr. Peter Chu, president and co-founder of Eclipse, said in a press release.